Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

Sensible Biotechnologies has successfully secured a $4.2 million pre-seed funding round aimed at enhancing its cell-based platform for the efficient manufacturing of high-quality mRNA. The funding, led by BlueYard Capital and supported by notable investors such as Y Combinator and Recode Health Ventures, will facilitate the optimization and scalability of the company's mRNA production capabilities. This initiative is vital as current manufacturing methods struggle with quality and scalability issues. The investment follows a strategic partnership with Ginkgo Bioworks (NYSE: DNA), which will help accelerate the development of Sensible's innovative platform. The funding marks a significant step towards unlocking the potential of mRNA technology for therapeutic applications.

Ginkgo Bioworks (NYSE: DNA) announced the acquisition of StrideBio’s adeno-associated virus (AAV) capsid discovery platform, enhancing its gene therapy capabilities. This transaction includes StrideBio's library of optimized capsids and preclinical data for a genetic heart disease asset. Ginkgo aims to leverage these resources to improve targeting and safety in gene therapies, addressing current limitations in the AAV field. The acquisition solidifies Ginkgo's position as a comprehensive service provider in gene therapy, with expectations to further develop and commercialize advanced gene therapies.

On April 4, 2023, Solvay announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA) to accelerate the development of sustainable biopolymers, bolstering its position in biotechnology. This multi-year agreement includes the acquisition of a Ginkgo lab in Cambridge, Massachusetts, enhancing Solvay's research capabilities. The partnership aims to leverage synthetic biology to produce environmentally-friendly materials and meet the increasing demand for sustainable solutions. Solvay's CEO highlighted this investment as a pivotal milestone for future growth.

Sensible Biotechnologies has announced a partnership with Ginkgo Bioworks (NYSE: DNA) to develop an in vivo microbial mRNA manufacturing platform. This collaboration aims to address the limitations of conventional in vitro transcription methods, which often struggle with scale and quality. The new method is expected to produce mRNA at a scale of over 100,000 liters, improving the quality and length of mRNA, thereby potentially unlocking new therapeutic applications. Both companies emphasize the need for more efficient mRNA production as the market expands.

Ginkgo Bioworks (NYSE: DNA) is scheduled to participate in Cowen's 43rd Annual Health Care Conference on March 6, 2023. CEO Jason Kelly will take part in a fireside chat at 9:10 a.m. ET and a SynBio & AI Driven Drug Discovery panel at 4:40 p.m. ET. This involvement highlights the company's strategy to showcase its leadership in the cell programming and biosecurity sectors. Investors can find more details, including webcast links and replays, on the company's investor relations website.

Ginkgo Bioworks Holdings reported a 52% increase in total revenue for 2022, reaching $478 million, exceeding guidance. The company added 59 new Cell Programs, marking 90% growth. Despite this, fourth-quarter revenue fell 34% to $98 million due to reduced COVID-19 testing services. Biosecurity revenue for 2022 was $334 million, up 66%. However, a loss from operations totaled $(2.2) billion, impacted by high stock-based compensation. Ginkgo forecasts at least $275 million in total revenue for 2023, with a plan to add 100 new Cell Programs and expects Biosecurity revenue of at least $100 million.

Ginkgo Bioworks (NYSE: DNA) will host a presentation and Q&A session on March 1, 2023, at 4:30 p.m. ET. This event will review the company's business performance for Q4 and the full year ending December 31, 2022. Details regarding the presentation and a link to the webcast will be available on Ginkgo's investor relations website. Investors can submit questions via Twitter or email prior to the event. Ginkgo Bioworks focuses on cell programming and biosecurity solutions across various industries including food, pharmaceuticals, and public health.

Zymtronix and Ginkgo Bioworks (NYSE: DNA) announced a partnership on February 16, 2023, to enhance enzymes for Zymtronix's cell-free biomanufacturing platform. This collaboration aims to optimize enzyme production for food, agriculture, cosmetics, and pharmaceuticals. Zymtronix's technology addresses challenges in traditional biocatalysis, enabling precise production across various sectors. Ginkgo will provide comprehensive support in enzyme engineering and production, facilitating the commercialization of sustainable ingredients. Both companies are eager to extend this partnership for a broader range of products.

Ginkgo Bioworks (NYSE: DNA) has partnered with the Rwanda Biomedical Centre (RBC) to initiate a one-year pathogen monitoring program at Kigali International Airport aimed at identifying new SARS-CoV-2 variants. This initiative, announced on February 15, 2023, involves monitoring wastewater samples from incoming flights and anonymous nasal swabs from international travelers, providing essential public health data to inform global mitigation strategies. The program enhances biosecurity and complements existing initiatives at U.S. airports. Ginkgo will supply support in collection, analysis, and bioinformatics, while RBC will manage operational tasks on-site.